Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2015

The Characterization of a Putative Virulence Factor Expressed By
Sneathia amnii
Amy Sanford
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Bacteriology Commons, Obstetrics and Gynecology Commons, and the Pathogenic
Microbiology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/3997

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

© Amy L. Sanford 2015
All Rights Reserved

	
  

	
  

	
  

THE CHARACTERIZATION OF A PUTATIVE VIRULENCE FACTOR
EXPRESSED BY SNEATHIA AMNII
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
By

AMY LYNN SANFORD
B.S., Virginia Polytechnic Institute and State University, 2011

Director: Kimberly K. Jefferson, Ph.D.
Associate Professor, Department of Microbiology and Immunology
Virginia Commonwealth University
Richmond, Virginia

Virginia Commonwealth University
Richmond, Virginia
September 2015

Acknowledgements
First and foremost, I would like to thank my mentor Dr. Kimberly Jefferson. Her
support and guidance throughout my graduate career have enabled me to become the
scientist that I am today. Her excitement and passion for science is an inspiration for all
those around her, and I am grateful I had the opportunity to be a member of her lab.
I would also like to thank the members of my committee, Dr. Cynthia Cornelissen
and Dr. Zhibing Zhang; their advice and guidance throughout my graduate career have
been instrumental in the successful completion of my project. I would also like to thank
Dr. Cornelissen and Dr. Gail Christie for allowing me to use their laboratory resources
and equipment.
I would like to sincerely thank the members of the Jefferson lab, past and
present: Dr. Jamie Brooks, Dr. Zhumei Cronk, Dr. Michael Harwich, Dr. Shreni Mistry,
Melissa Prestosa, Rana Mehr, Matthew Allen-Daniels, and Abdallah Abdelmaksoud. I
am so fortunate to have had so many amazing labmates who not only provided me with
scientific advice and guidance, but also laughter, support, and friendship. I would also
like to thank members of the Cornelissen and Christie labs for their advice, support, and
humor.

	
  

ii	
  	
  

	
  

Dedication
	
  

I would like to dedicate this work to my amazing family: my parents, Bill and

Allison Sanford, my brother, Billy, and my grandparents, Danny and Margaret Campbell.
My successes, both in graduate school and throughout life, would not have been
possible without their unwavering support and love. I am so lucky to have such an
amazing group of people in my life.
I would also like to dedicate this work to my incredible fiancé, Adam Rupert. He
has been instrumental in my success as a graduate student; from quizzing me on test
material to accompanying me back to VCU for late-night timepoints, he has always
been willing to do whatever it takes to see me succeed. I am so grateful for his love and
support.

	
  

	
  
iii	
  

	
  

Table of Contents

Page
Acknowledgements……………………………………………………….……………..ii
Dedication…………………………………………………...…………………………..iii
List of Figures…..…………………………………………………….………………….v
List of Tables.………………………………………………………….……...………..vii
List of Abbreviations…………….…………………………………………...………..viii
Chapter
1. Introduction………………………………..…………………………………......….1
I. Bacterial Vaginosis…………………………………………………………..1
II. Preterm Birth………………………………………………………………….4
III. Microbial Invasion of the Amniotic Cavity…………………..............…....6
IV. Sneathia amnii………………………………………………………..……..9
V. Research Objectives………………………………………...……………..13
2. Materials and Methods………………………………………………..…………..15
3. Results…………………………………………….……………………………..…32
I. Sn35 is Cytopathogenic to Host Cells…………………………………….32
A. Cytotoxicity to HAECs……………………………………………...…32
B. Cytotoxicity to JEG-3 cells……………………………………………35
C. Cytotoxicity to VK2 cells…………………………………………...…35
II. Adherence and Invasion of Host Cells by Sn35………………………...42
A. Adherence and Invasion of HAECs………………………………....42
B. Adherence and Invasion of JEG-3 cells…………………..………...47
C. Adherence and Invasion of VK2 cells……………………………….47
III. Identification of Putative Virulence Gene in Sn35……………………...58
IV. Polyclonal Antiserum Production Using TvbA Peptide………………..65
A. Identification of Antigenic Epitopes within TvbA…………………...66
B. Expression and Purification of Recombinant AS01………………..69
C. Characterizing the Expression of TvbA in Sn35 Using AS01
Antiserum…………………………………………………………………78
D. Inhibiting Cytotoxicity, Adherence, and/or Invasion Using
AS01 Antiserum…………………………………………………………..85
4. Discussion…………………………………….……………………………………90
Literature Cited……………………………….…………………………………………..……94
Vita………………………………………………………………………………………………99

	
  

	
  
iv	
  

	
  

List of Figures

Page
Figure 1: Model of microbial invasion of the amniotic cavity (MIAC)……………………...8
Figure 2: Putative Type II restriction-modification system expressed by S. amnii strain
Sn35………………………………………………………………………………………….....12
Figure 3: Loss of cell integrity of HAECs due to incubation with Sn35..…………………34
Figure 4: Loss of cell integrity of JEG-3 cells due to incubation with Sn35………...…...37
Figure 5: Loss of viability of JEG-3 cells due to incubation with Sn35.…………….……39
Figure 6: Loss of cell integrity of VK2 cells due to incubation with Sn35………..………41
Figure 7: Loss of viability of VK2 cells due to incubation with Sn35……………..………44
Figure 8: Invasion of Sn35 into HAECs.……….…...………………………..…….……… 46
Figure 9: Z-stack of Sn35 invasion into HAECs……………………….….………………..49
Figure 10: Invasion of Sn35 into JEG-3 cells…………………………..……….....…….…51
Figure 11: qPCR-based recovery of Sn35 after incubation with JEG-3 cells.…………..53
Figure 12: Adherence and invasion of JEG-3 cells by Sn35…………………….….…….55
Figure 13: Invasion of Sn35 into VK2 cells..………………………...…………….………..57
Figure 14: qPCR-based recovery of Sn35 after incubation with VK2 cells.…….……….60
Figure 15: Adherence and invasion of VK2 cells by Sn35…………………………...……62
Figure 16: Type Vb two-partner secretion system expressed by Bordetella pertussis,
and putatively expressed by Sn35..………………………..……………………………..…64

	
  

v	
  	
  

	
  

Figure 17: In silico prediction of antigenic epitopes within TvbA…………………...…….68
Figure 18: PCR amplification of AS01 DNA…………………………...……………………71
Figure 19: Schematic representation of the pET32xT-AS01 plasmid…………...……….73
Figure 20: Restriction digest confirmation of pET32xT-AS01 candidates in chemically
competent E. coli cells..…………………………………………………………….…………75
Figure 21: Confirmation of induced AS01 with 1 mM IPTG at 30°C……………………..77
Figure 22: Purification of recombinant AS01……………………………………………….80
Figure 23: Characterization of the subcellular location of TvbA in Sn35……….…….….82
Figure 24: Temporal expression of TvbA by Sn35………………………..…………….…84
Figure 25: Inhibition of Sn35 cytotoxicity to JEG-3 cells……………………………..……87
Figure 26: Inhibition of Sn35 adherence to HAECs…………………………...……….…..89

	
  

	
  
vi	
  

	
  

List of Tables

Page
Table 1: Plasmids and strains used in this study…………………………………………..16
Table 2: Primers used in this study………………………………………………………….22

	
  

	
  
vii	
  

	
  

List of Abbreviations

°C
µg
µL
AF
Amp
AmpR
B. pertussis
BHI
bp
BSA
BV
CFU
Cm
CmR
DNA
dNTP
E. coli
EDTA
FBS
g
gDNA
HAEC
HS
IPTG
IVF
JEG-3
kb
kDa
L
LB
M
max
Mb
Me-180
mg
MIAC
mL
mM

	
  

degrees Celsius
microgram
microliter
amniotic fluid
ampicillin
ampicillin resistance
Bordetella pertussis
brain-heart infusion
base pair
bovine serum albumin
bacterial vaginosis
colony forming unit
chloramphenicol
chloramphenicol resistance
deoxyribonucleic acid
deoxynucleotide triphosphate
Escherichia coli
ethylenediamine tetraacetic acid
fetal bovine serum
gram
genomic DNA
human amniotic epithelial cell
human serum
isopropyl β-D-1-thiogalactopyranoside
in vitro fertilization
human chorionic trophoblasts
kilobase pairs
kilodalton
liter
Luria-Bertani
molar
maximum
megabase
human cervical carcinoma cells
milligram
microbial invasion of the amniotic cavity
milliliter
millimolar

	
  
viii	
  

	
  

MW
MWCO
nm
OD
PBS
PBST
PCR
PPROM
PVDF
qPCR
rpm
S. amnii
sBHI
SDS
Sn35
SOC
STD
TAE
UV
V
VK2

	
  

molecular weight
molecular weight cut off
nanometer
optical density
phosphate buffered saline
PBS supplemented with 0.05% Tween 20
polymerase chain reaction
preterm premature rupture of membranes
polyvinylidene fluoride
quantitative PCR
revolutions per minute
Sneathia amnii
supplemented brain-heart infusion
sodium dodecyl sulfate
Sneathia amnii strain 35
super optimal broth with catabolite repression
sexually transmitted disease
tris-acetate-EDTA buffer
ultraviolet
volt
human vaginal keratinocytes

	
  
ix	
  

	
  

Abstract

THE CHARACTERIZATION OF A PUTATIVE VIRULENCE FACTOR EXPRESSED BY
SNEATHIA AMNII
By Amy L. Sanford
B.S., Virginia Polytechnic Institute and State University
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University
2015
Major Director: Kimberly K. Jefferson, Ph.D.
Associate Professor, Department of Microbiology and Immunology

Preterm birth, defined at birth before 37 weeks gestation, affects millions of
newborns worldwide every year. Preterm birth is a leading cause of infant morbidity and
mortality. One major cause of preterm birth is preterm premature rupture of membranes
(PPROM), which can be triggered by bacterial infection and inflammation. A bacterial
species that has been implicated in preterm birth and other obstetric complications is
Sneathia amnii. The goals of this study were to observe cytopathogenic effects caused
by S. amnii strain Sn35 and identify putative virulence factors causing those effects.
Sn35 was able to adhere to, invade, and damage/kill various host cell lines. We

	
  

	
  

	
  

characterized these virulence attributes. A putative virulence determinant was identified,
and a fragment of the protein was expressed for polyclonal antiserum production.
Antiserum was used to characterize the expression and subcellular localization of the
protein in Sn35. However, antiserum was unable to prevent cytopathogenic effects.

	
  

	
  

	
  

Introduction

I.

Bacterial Vaginosis
Bacterial vaginosis (BV) is the most common vaginal disorder in women of

reproductive age. A national survey conducted from 2001-2004 estimated that BV
affects roughly 29% of women ages 14-49 in the United States1. The development of
BV is correlated with an imbalance of bacteria in the vagina; this imbalance is
characterized by a decrease in healthy vaginal microorganisms and an increase in
pathogenic microorganisms.
Lactobacillus species are usually the predominant bacteria found in healthy
vaginal microflora2. As their name implies, lactobacilli are lactic acid-producing bacteria;
lactic acid in the vagina helps to keep the pH at an acidic level. The acidity of the vagina
is important, as it prevents many pathogenic microorganisms from colonizing and
causing infections. Some lactobacilli can also produce hydrogen peroxide, which is toxic
to pathogenic bacteria. The protectiveness of lactobacilli varies by species;
Lactobacillus crispatus, for example, is known to be a protective species, due to the fact
that most strains can produce hydrogen peroxide3. Conversely, Lactobacillus iners is
considered a less protective species, as most strains do not produce hydrogen
peroxide4. Reasons for the decrease in healthy vaginal bacteria have not yet been
identified; however, studies have shown that colonization by less protective
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Lactobacillus species are related to positive cases of BV5. There are several pathogenic
microorganisms associated with BV, a predominant one being Gardnerella vaginalis. It
was originally believed that G. vaginalis was the etiological cause of BV. However, not
all women who test positive for BV are colonized with G. vaginalis6, and colonization
with G. vaginalis does not always lead to BV. Therefore, BV is now considered a
complex, polymicrobial disorder.
A multitude of risk factors for developing BV have been identified through various
studies; these factors include but are not limited to vaginal douching7, new or multiple
sexual partners8, the use of intrauterine contraceptive devices (IUDs)9, smoking8, and
stressful life events10. Once developed, BV dramatically increases the risks of several
complications, such as the susceptibility to HIV and other STIs11 and infection following
surgical procedures, such as hysterectomies or abortions12, 13. If a pregnant woman
develops BV, the risk of pregnancy complications, such as preterm birth and low birth
weight, also increases14.
BV can present as a symptomatic or asymptomatic disorder, although roughly
half of all BV cases are asymptomatic15. Symptoms can include abnormal vaginal
discharge or odor, painful urination, and/or general vaginal pain. Diagnosis of BV can
occur via two methods; the first method, the Amsel criteria, utilizes 4 different
characteristics for a positive BV diagnosis. The first characteristic is the presence of a
white or gray, thin, homogenous vaginal discharge. The second is the detection of clue
cells via microscopy; clue cells are vaginal epithelial cells that have a distinct stippled
appearance due to being covered with bacteria. The third characteristic is a vaginal fluid
pH above 4.5, as the pH of a healthy vagina is under 4.516. The fourth and last
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characteristic is the presence of an amine odor upon adding 10% potassium hydroxide
solution. In order to confirm a positive BV diagnosis, 3 out of the 4 criteria mentioned
must be present.
The second method for diagnosing BV, the Nugent criteria, involves using a
Gram-stained vaginal smear to score the types and amounts of bacteria present. The
scoring system is used to quantify the amount of long Gram-positive rods versus shorter
Gram-negative rods and cocci. The decrease in Gram-positive rods, such as
Lactobacillus species, is scored from 0 to 4 (with a score of 4 equaling the highest
decrease in Gram-positive rods). The presence of small gram-variable and Gramnegative rods, such as G. vaginalis, Prevotella species, etc., is scored from 0 to 4. The
presence of curved Gram-negative rods, such as Mobiluncus species, is scored 0 to 217.
Scores of 7 to 10 are consistent with cases of bacterial vaginosis.
For the treatment of nonpregnant woman, the CDC currently recommends an
antibiotic regimen of 500 mg metronidazole 2x a day for a week, 0.75% metronidazole
gel (5 g) once a day for 5 days, or 2% clindamycin cream (5 g) once a day for a week18.
Treatment is recommended for symptomatic pregnant women, but antibiotic regimens
are altered from those of nonpregnant women18.
As mentioned previously, studies have estimated that BV affects 29% of women
in the United States1. African American women have a three-fold higher risk of bacterial
vaginosis compared to Caucasian women (10-20% in Caucasian women, 30-50% in
African American women); estimates can vary based upon the populations studied19, 20.
In addition to the increased likelihood of developing BV, African American women are
also twice as likely to experience preterm birth and have a three-fold higher risk of very
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preterm birth21, 22. In a recent study, DNA extraction and 16S rRNA gene analysis of
mid-vaginal isolates obtained from pregnant African American women and pregnant
women of European ancestry revealed very significant differences in each group’s
vaginal microbiome23. While European ancestry women are predominantly colonized
with Lactobacillus species, the vaginal microbiomes of African American women are
more diverse. Several bacterial taxa, such as Gardnerella, Mycoplasma, and Sneathia,
were found more frequently in the microbiomes of African American women. These taxa
are also associated with cases of preterm birth and microbial invasion of the amniotic
cavity.

II.

Preterm Birth
Preterm birth, defined as birth before 37 completed weeks of pregnancy, affects

an estimated 15 million newborns worldwide every year24. Preterm birth can be caused
by a number of factors, including premature rupturing of the amniotic sac and release of
amniotic fluid. While rupturing of these membranes can occur shortly before term labor
and is termed premature rupture of membranes (PROM), rupture prior to 37 weeks
gestation is defined as preterm PROM (PPROM). One-third of all preterm births are
associated with PPROM25.
Preterm birth is a leading cause of infant morbidity and mortality worldwide26.
Infants born prematurely may suffer from a myriad of problems, including breathing and
feeding difficulties27, 28, hearing and vision impairments29, and developmental delays30;
studies have also associated preterm birth with cerebral palsy31. Complications of
preterm birth vary based on gestational age; preterm births are defined as extremely
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preterm (<28 weeks), very preterm (28 to <32 weeks), or moderate to late preterm (32
to <37 weeks)32, with the worst complications associated with younger gestational age.
Many risk factors have been correlated with experiencing preterm birth. While
environmental factors such as stress33 and socioeconomic status34 have been
associated with preterm labor, physical factors also play a significant role. Having
previously experienced a premature birth35, multiple gestations (carrying twins, triplets,
etc.)36, irregularities in reproductive organs (such as a short cervix or shortening of the
cervix early in pregnancy)37, being underweight or overweight before pregnancy38, 39,
and conception using in vitro fertilization (IVF)40 are physical factors that may increase
the risk of preterm birth. As previously mentioned, race has also been correlated to
preterm birth risk. Of the factors listed, experiencing previous preterm births is the
greatest risk for a new preterm birth35.
Two additional factors have been associated with the development of PPROM.
The first, weakening of fetal membranes, is another normal process that occurs at the
onset of labor. However, if it occurs preterm, it can contribute to a premature delivery.
Fetal membranes can be weakened due to collagen degradation by matrix
metalloproteinases (MMPs). Various types of collagen are present in placental
membranes. Studies have found that amniotic fluid isolated from cases of PPROM have
higher levels of MMPs41, 42. The second factor, infection, has become a major target of
interest. Bacterial infections and inflammation triggered by infections could contribute to
weakened membranes and development of PPROM. Some bacterial factors, like
lipopolysaccharides (LPS), have the ability to increase MMP expression43. Furthermore,
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bacteria have been isolated from amniotic fluid obtained from PPROM44, indicating that
the bacteria are able to ascend into and invade the amniotic cavity.

III.

Microbial Invasion of the Amniotic Cavity
Microbial invasion of the amniotic cavity (MIAC) is defined by a culture of

amniotic fluid (AF) that tests positive for the presence of bacteria. While less than 1% of
AF samples isolated from women at term tested positive for bacteria, 12.8% of AF
samples isolated from patients experiencing preterm birth with intact membranes gave
positive results45. The same study discovered that 32.4% of AF samples obtained from
women experiencing PPROM tested positive for bacteria. Rates may be falsely low due
to failure to cultivate certain fastidious organisms.
Little is known about how bacteria gain access to the amniotic fluid; it is currently
thought that vaginal bacteria traverse the cervical mucus plug and enter the uterine
cavity46. This is a difficult route, as mucus plugs form specifically to act as a barrier
between the vagina and the uterine cavity. Furthermore, the mucus plug contains a
number of antimicrobial agents that aid in blocking bacterial infection47. After getting
past the mucus plug, bacteria can remain in the uterine cavity, traverse into the
placental membranes, causing chorioamnionitis, or completely pass though the
placental membranes and access the amniotic fluid (Figure 1). Bacteria can trigger
intraamniotic inflammation, leading to an increase in a number of factors such as IL-648,
TNF-α49, or MMP-850. These inflammatory markers, specifically MMP-8, can degrade
collagen present in the placental membranes, weakening them. The inflammatory
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Figure 1. Model of microbial invasion of the amniotic cavity (MIAC). This is the
currently accepted model for how microbes are able to access and invade the amniotic
environment. It is thought that bacteria (shown in red) ascend through the cervical
mucus plug and into the uterine cavity. Once in the uterus, they can invade the chorion
layer of the placenta (indicated by the tan cells), and cause chorioamnionitis.
Furthermore, they can travel through the fetal membranes (indicated by the gray cells)
and access the amniotic fluid (which would be located above the gray cells).
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Reprinted by permission from Macmillan Publishers Ltd: Nature – Laboratory
investigations. Kim, M. J., et al., Widespread microbial invasion of the chorioamniotic
membranes is a consequence and not a cause of intra-amniotic infection. Laboratory
investigation; a journal of technical methods and pathology 2009, 89 (8), 924-36.
Copyright 2009.
http://www.nature.com/labinvest/journal/v89/n8/full/labinvest200949a.html
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response can also trigger uterine muscle contractions. Collectively, these
consequences can lead to PPROM and preterm birth51.
Several microorganisms have been associated with MIAC, PPROM, and preterm
birth. Gardnerella vaginalis, Mycoplasma hominis, Fusobacterium species, Ureaplasma
species, and Sneathia species have all been detected in PCR-based studies of MIAC52,
53

. Many studies utilize non-culture, DNA-based methods, as many microbial species

have yet to be cultivated54. DNA-based methods are not able to distinguish between live
and dead microorganisms, but can detect microorganisms that culture-based methods
might not55.

IV.

Sneathia amnii
Sneathia amnii is a Gram-negative anaerobic bacterium, and is a member of the

Fusobacteriaceae family. Formerly grouped with the genus Leptotrichia, Sneathia
species have been isolated as part of normal reproductive microflora and in association
with obstetric complications56, 57. Sneathia has been associated with bacterial vaginosis,
preterm labor, and postpartum bacteremia, and has been associated with STDs. It is
also one of the most common genera found in amniotic fluid. A novel species, Sneathia
amnii, was isolated and characterized by the Vaginal Human Microbiome Project at
Virginia Commonwealth University. The specific strain was isolated from a mid-vaginal
sample obtained from an African American woman experiencing symptoms of preterm
labor at 26 weeks gestation; this type strain was designated Sn3558.
Sn35 possesses a genome that is 1.34 Mbp in size; to date, this is the smallest
genome in the Fusobacteriaceae family. The GC content of the genome is roughly 28%,
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and an estimated 1,282 putative protein-encoding genes exist within the genome58.
Analysis of the genome identified genes for glucose, maltose, glycogen, and
glucosamine metabolism; however, Sn35 is unable to ferment mucin, starch, fructose,
galactose, mannose, or sucrose. While Sn35 does not encode enzymes to synthesize
the majority of amino acids, it appears to thrive via utilization of host factors58.
Antibiotic resistance of this strain was also studied. As is true for most Gramnegative organisms, Sn35 is highly resistant to nafcillin. However, Sn35 tests sensitive
to vancomycin, which is contrary to most Gram-negative organisms. Sn35 is also
sensitive to metronidazole, which is commonly used to treat bacterial vaginosis58.
Several genes of interest were identified during analysis of the Sn35 genome. A
putative DNA restriction-modification system was discovered; this system was predicted
to be acting as a Type II system (Figure 2). Additionally, several genes were predicted
to encode proteins present in Type II protein secretion systems. A large protein with
homology to hemagglutinin domains and hemolysins was identified, yet
hemagglutination of human red blood cells was not detected58. Sn35 exhibits weak
hemolytic activity, but requires the presence of human blood to grow on agar plates.
Human serum is required for growth in liquid culture. Attempts to use Brucella sheep’s
blood agar or fetal bovine serum for Sn35 growth were unsuccessful58; these results
demonstrate the specificity of Sn35 for its human host. This could be due to humanspecific growth factors present in blood and serum.
Although very little is known about this organism, due to its implications in both
bacterial vaginosis and preterm birth, S. amnii strain Sn35 appears to be a great focus
for further research in the context of reproductive and neonatal health. Furthermore, its
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Figure 2. Putative Type II restriction-modification system expressed by S. amnii
strain Sn35. A) Orange represents the restriction enzyme, while green represents both
the methyltransferase (MT) and the methylation (M) present on DNA. B) The
methyltransferase will methylate genomic DNA, while the restriction enzyme can
recognize foreign DNA and attack unmethylated sites. Figure adapted from Ishikawa et
al., 201059.
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specificity for human blood products strongly implies its exclusive niche in humans. Its
contributions to MIAC, PPROM, and preterm birth, as well as vaginal health as a whole,
need to be further elucidated.

V.

Research Objectives
As previously mentioned, Sneathia is one of the most common bacterial genera

found in amniotic fluid; in addition, Sneathia has been implicated in a number of
obstetric complications. Furthermore, previous work has demonstrated that S. amnii
strain Sn35 is both cytotoxic and adherent to Me-180 human cervical cells58. These
results suggest both the production of virulence factors by S. amnii and a possible
mechanism of pathogenicity. Therefore, the goal of this study is to further characterize
the pathogenicity of Sn35 in preterm birth. Three objectives were established for this
study:

1. Determine pathogenic effects that Sn35 has on a variety of immortalized and
primary cell lines. It was hypothesized that in order to invade the amniotic cavity and
exist in amniotic fluid, bacteria must be able to damage and/or traverse one or more
host cell barriers present during pregnancy. This was addressed by performing various
host cell assays in the presence of Sn35 to determine pathogenic effects.
2. Identify the putative virulence factor responsible for the observed pathogenic
effects. It was hypothesized that in order to exert a pathogenic effect on host cells, Sn35
must be producing a virulence factor. This was addressed by performing bioinformatic
analyses to determine whether Sn35 encoded genes with similarity to known virulence
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factors.
3. Characterize the function of the putative virulence factor. It was hypothesized
that the virulence factor could be acting as a cytotoxin or adhesin, allowing for either
adherence/invasion of host cells or cell damage/death. This was addressed by
attempting to clone and express the putative virulence factor in E. coli; later, polyclonal
antiserum was used to better characterize the protein.
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Materials and Methods

Bacterial Strains and Culture Conditions
The bacterial strains and plasmids used in this study are listed in Table 1.
Sneathia amnii strain Sn35 was grown and maintained anaerobically on supplemented
brain heart infusion (sBHI) plates containing 1.5% (w/v) BactoAgar (BD, Franklin Lakes,
NJ), 3.7% (w/v) BHI (Thermo Scientific, Waltham, MA), 1% (w/v) gelatin, 1% (w/v) yeast
extract, 0.1% (w/v) starch, 0.1% (w/v) dextrose, and 10% whole human blood
(BioChemed Services, Winchester, VA).
Participants were recruited from outpatient clinics at the Virginia Commonwealth
University Medical Center from 2009-2013 as part of the Human Vaginal Microbiome
project. The Institutional Review Boards for Human Subjects Research at VCU (Panel
B) and the Virginia Department of Health reviewed and approved this study. Strain Sn35
was obtained through this study. Liquid cultures of Sn35 were grown anaerobically in
sBHI broth containing 10% pooled human serum (HS) (MP Biomedicals, Santa Ana,
CA). All cultures were grown under anaerobic conditions in a BacBasic anaerobic
incubator (ShelLab, Cornelius, OR) containing a gas mix of 5.0% carbon dioxide, 5.0%
hydrogen, and nitrogen as the balance gas.
sBHI + chocolate agar plates were used for recovery of bacteria during
adherence and gentamicin protection assays. Whole human blood was added to
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Table 1. Plasmids and bacterial strains

Plasmids
pCR4-TOPO-AS01

Source

pCR4-TOPO vector with
TvbA fragment AS01
cloned in
pET32xT vector with TvbA
fragment AS01 cloned in

This study

S. amnii Strains
Sn35

Description
Mid-vaginal isolate
obtained from patient
experiencing preterm birth
at 26 weeks gestation

Source
Harwich et al. (2012)

E. coli Strains
CH3 Blue

Description
Chemically competent cells
derived from E. coli K12,
cloning strain
Electrocompetent cells
derived from E. coli BL21,
recombinant protein
expression strain (CmR)
BL21-CodonPlus(DE3)-RIL
cells containing TvbA
peptide fragment (AS01)
cloned into pET32xT
(AmpR, CmR)

Source
Bioline (Tauton, MA)

pET32xT – AS01

BL21CodonPlus(DE3)-RIL
BL21 + pET32xT +
AS01

	
  

Description
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This study

Stratagene (La Jolla, CA)

This study

	
  

autoclaved sBHI agar to achieve a final concentration of 10%. The mixture was placed
at 80°C for 30 minutes prior to pouring in order to achieve whole blood lysis. sBHI +
chocolate agar plates were made with a concentration of 1% (w/v) BactoAgar.
E. coli strains were grown aerobically in LB at 37°C and 200 rpm. Appropriate
antibiotics were added at the following concentrations: 100 µg/mL ampicillin (Amp) for
E. coli, and 35 µg/mL chloramphenicol (Cm) for E. coli.

Agarose Gels
1% agarose gels were prepared by dissolving agarose in 1X tris-acetate-EDTA
(TAE) buffer. Ethidium bromide was added to the gel at a final concentration of 1 µg/mL
before pouring. 5X DNA loading buffer blue (Bioline, Taunton, MA) was added to the
DNA samples to achieve a 1X final concentration. Gels were run at 124 volts and
visualized under ultraviolet (UV) light. DNA size was determined by comparison against
the Hyperladder series of molecular weight marker (Bioline, Taunton, MA).

Cell Lines
JEG-3 human chorionic trophoblasts (ATCC, Manassas, VA) were cultured at
37°C in 5% CO2 in minimum essential media (EMEM) (Quality Biological, Gaithersburg,
MD) supplemented with 10% fetal bovine serum and 1 IU mL-1 penicillin/streptomycin
(Life Technologies, Carlsbad, CA). VK2/E6E7 human vaginal keratinocytes (ATCC,
Manassas, VA) were cultured at 37°C in 5% CO2 in keratinocyte-SFM (Life
Technologies, Carlsbad, CA) supplemented with human recombinant Epidermal Growth
Factor 1-53, Bovine Pituitary Extract, and 1 IU mL-1 penicillin/streptomycin (Life
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Technologies, Carlsbad, CA). Primary human amniotic epithelial cells (HAECs) were
isolated from healthy, full-term placentas obtained via C-section (MCV, Richmond, VA).
Cells were cultured at 37°C in 5% CO2 in DMEM/F12 (1:1) (Life Technologies,
Carlsbad, CA) supplemented with 10% fetal bovine serum and 1 IU mL-1
penicillin/streptomycin (Life Technologies, Carlsbad, CA).

Trypan Blue Cytotoxicity Assay
Twenty-four-well polystyrene plates (CellTreat, Shirley, MA) were seeded with
respective cell lines. Once a monolayer of cells had formed, growth medium was
removed, the host cell monolayer was washed twice with sterile 1X PBS, and fresh
growth medium was added. Bacterial cultures were grown overnight in 2 to 3 mL of
SBHI/HS, and diluted to an OD600nm of 0.1. Bacterial cultures were grown overnight in 2
to 3 mL of SBHI/HS, and diluted to an OD600nm of 0.1. Bacterial cells were resuspended
in cell growth medium, and 100 µL of the suspension was added to each well. After a 4
hour incubation with bacteria, host cell wells were washed 3 to 4 times with sterile 1X
PBS. A 1:1 ratio solution of trypan blue (Thermo Scientific, Waltham, MA): sterile 1X
PBS was added to the cell wells for 4 minutes. The trypan blue solution was removed,
and images of each well were taken with an EVOS AMEX-100 microscope (Life
Technologies, Carlsbad, CA).

MTT Cytotoxicity Assay
Twenty-four-well polystyrene plates (CellTreat, Shirley, MA) were seeded and
incubated as previously described. Growth medium was removed, the host cell
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monolayer was washed twice with sterile 1X PBS, and fresh growth medium was
added. Bacterial cultures were grown overnight in 2 to 3 mL of SBHI/HS, and diluted to
an OD600nm of 0.1. Bacterial cells were resuspended in cell growth medium, and 100 µL
of the suspension was added to each well. The plates were centrifuged at 500 rpm for 1
minute to maximize contact between the bacteria and the host cells. After a 4 hour
incubation with bacteria, host cell wells were washed 3 to 4 times with sterile 1X PBS
and fresh growth medium was added. MTT (EMD Millipore, Billerica, MA) was added to
each well, and the plates were centrifuged using the settings previously mentioned to
maximize contact between the MTT reagent and the cells. The plates were incubated
for 2 hours at 37°C in 5% CO2. After incubation, MTT stop solution was added
according to the manufacturer’s instructions. Cells were transferred to a 96-well plate
(CellTreat, Shirley, MA) for A570 and A630 readings using a plate reader (BioTek,
Winooski, VT). Absorbance values were detected with a 1:1 mix of MTT reagent and
stop solution alone; therefore, these values were subtracted from the experimental
values obtained. Untreated (control) cell viability was normalized to 100% for each MTT
assay.

Bacterial Adherence Assay
Twenty-four-well polystyrene plates (CellTreat, Shirley, MA) were seeded and
incubated as previously described. Growth medium was removed, the host cell
monolayer was washed twice with sterile 1X PBS, and fresh growth medium was
added. Bacterial cultures were grown overnight in 2 to 3 mL of SBHI/HS, and diluted to
an OD600nm of 0.1. Bacterial cells were resuspended in cell growth medium, and 100 µL

	
  

	
   19	
  

	
  

of the suspension was added to each well. After a 1 hour incubation with bacteria, host
cell wells were washed 3 to 4 times with sterile 1X PBS. Water was added to each well
in order to lyse the host cells. The bottoms of the wells were scraped vigorously with a
pipet tip, and all contents were collected and placed in a 1.5 mL microcentrifuge tube.
The contents were serially diluted and plated onto sBHI + chocolate agar plates.
Alternatively, after washing 3 to 4 times with sterile 1X PBS, DNA from each well was
extracted using a PowerSoil DNA isolation kit (MO BIO Laboratories, Carlsbad, CA).

Gentamicin Protection Assay
Twenty-four-well plates (CellTreat, Shirley, MA) were seeded and incubated as
previously described. Assays were performed as described previously for bacterial
adherence assays, except bacterial cultures were diluted to an OD600nm of 0.001. After a
1 hour incubation with bacteria, host cell wells were washed 3 to 4 times with sterile 1X
PBS and antibiotic-free cell media was added. Gentamicin was added to each well at a
final concentration of 100 µg/mL. Cells were incubated at 37°C in 5% CO2 for 1 hour,
then washed 2 to 3 times with sterile 1X PBS. Water was added to each well in order to
lyse the host cells. The bottoms of the wells were scraped vigorously with a pipet tip,
and all contents were collected and placed in a 1.5 mL microcentrifuge tube. The
contents were serially diluted and plated onto sBHI + chocolate agar plates.

Adherence/Invasion Assay Utilizing Confocal Microscopy
Confocal assays were performed as previously described60 with slight
modifications. Individual glass bottom plates (MatTek, Ashland, MA) were seeded with
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respective cell lines. Once a monolayer of cells had formed, growth medium was
removed, the cell monolayer was washed twice with sterile 1X PBS, and stained with
2.5 µL/mL per plate of Vybrant DiI (Invitrogen, Grand Island, NY) membrane stain
(Invitrogen, Grand Island, NY) for 15 minutes at 37°C in 5% CO2. After incubation, cells
were washed twice with sterile 1X PBS to remove excess stain.
Bacterial cultures were grown overnight in 2 to 3 mL of SBHI/HS, and diluted to
an OD600nm of 0.150. 1.4 mL of the culture was centrifuged to collect the cells. Bacterial
cells were washed twice with sterile 1X PBS and stained with 5 µL of BacLight green
bacterial stain (Invitrogen, Grand Island, NY) in 1 mL 1X PBS. Bacterial cells were
incubated with the stain for 15 minutes at 37°C in 5% CO2, then washed twice with 1X
PBS to remove excess stain. 100 µL of bacteria in 1 mL 1X PBS were added per
individual plate of host cells. Plates were incubated for 15 minutes at 37°C in 5% CO2.
Cell monolayers were washed twice with sterile 1X PBS to remove nonadherent
bacteria. Plates were analyzed by confocal microscopy using a Zeiss LSM 710 Confocal
Microscope. Microscopy was performed at the VCU – Dept. of Anatomy and
Neurobiology Microscopy Facility, supported, in part, by funding from NIH-NINDS
Center Core Grant 5 P30 NS047463 and, in part, by funding from NIH-NCI Cancer
Center Support Grant P30 CA016059.

Quantitative Polymerase Chain Reaction (qPCR)
DNA isolated from adherence/invasion assays was used to determine the relative
amount of adhesive/invasive bacteria using 16S primers. The reaction mix was
composed of 5 µL of undiluted DNA, 10 pmol of both the forward and reverse primers,
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Table 2. Primer List

Primer Name
Sequence
AgSn35Fwd
5’ ATGATGGGATCCGCAGAAAATATTTCAAAAAC 3’
AgSn35Rev
5’ ATGATGCTCGAGTTGACCAGAGTTAGCTTCTACTTTAC 3’
SnRTFwd
5’ TGATCCAGCAATTCTGTGTG 3’
(for qPCR)
SnRTRev (for 5’ TAGGCAAGCCTATGGTTGAG 3’
qPCR)
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5.5 µL sterile water, and 12.5 µL iTaq Universal SYBR Green Supermix (Bioline,
Tauton, MA). qPCR was performed in an iQ5 Multicolor Realtime PCR Detection
system (BioRad, Hercules, CA) following the programmed steps: 1 cycle at 94°C for 2
minutes, 45 cycles of 94°C for 15 seconds, 52°C for 15 seconds, 71°C for 15 seconds
while collecting real time-PCR readings, and 31 cycles of 65°C for 10 seconds while
collecting melting curve recordings. Data was recorded in cycle threshold (Ct) for each
sample in technical triplicate, averaged, and normalized by calculating 2(-Ct). Ratios were
determined between input control values and experimental values to determine
differences in amount of bacteria.

In silico Prediction of Antigenic Regions
The amino acid sequence of TvbA was submitted to an antigenic peptide
predictor, which predicted the segments within the protein sequence likely to be
antigenic using the methods of Kolaskar and Tongaonkar61.

Polymerase chain reaction (PCR) and Product Purification
Reaction mixtures were generally 50 µL total volume composed of 10 µL 5X
Phire buffer (Thermo Scientific, Waltham, MA), 1 µL 10 mM dNTPs (2.5 mM of each),
10 pmol of both the forward and reverse primers, DNA template, and 1 µL Phire II
polymerase in sterile water. For reactions using gDNA as template, the template was
diluted 1:10 and 1 µL was used as template. Reaction conditions were programmed into
a thermal cycler machine as: hot start at 105°C, initial denaturation at 98°C for 1 minute,
followed by 35 cycles of 98°C for 30 seconds, 54°C for 30 seconds, 72°C for 45
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seconds, and a round of final extension at 72°C for 5 minutes. Resulting PCR products
were purified after agarose gel electrophoresis using the QIAquick Gel Extraction kit
(Qiagen, Valencia, CA), following the manufacturer’s instructions.

Plasmid DNA Purification and Manipulation
Plasmid purifications were performed using the QIAprep Spin Miniprep kit
(Qiagen, Valencia, CA) according to the manufacturer’s instructions, using overnight
cultures of E. coli single colony transformants in 3 mL LB containing the appropriate
antibiotic. All restriction enzymes, specific buffers, and BSA used for restriction digests
of plasmid DNA or PCR products were purchased from New England Biolabs (Ipswich,
MA) and used according to the respective manufacturer’s recommendations. After
restriction digest, the 5’ phosphoryl groups were removed using Antarctic Phosphatase
and supplied buffer (New England Biolabs, Ipswich, MA) according to manufacturer’s
instructions. Ligation of DNA fragment inserts into digested plasmids was accomplished
using Ready-To-Go T4 DNA Ligase (Amersham Biosciences, Piscataway, NJ).

Transformation of Chemically Competent E. coli
One vial of CH3-Blue chemically competent E. coli cells (Bioline, Taunton, MA)
was thawed on ice; 3 µL of the plasmid ligation reaction were added and incubated on
ice for 20 minutes. The tube was transferred to a 42°C waterbath for 30 seconds; 250
µL of SOC media (2% Bacto tryptone, 0.5% Bacto yeast extract, 10mM NaCl, 2.5mM
KCl, 10mM MgSO4, 10mM MgCl2, 20mM glucose) was immediately added to the tube
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after removal from the waterbath. The cells recovered at 37°C for 1 hour, and were then
plated on LB plates with the appropriate antibiotic selection.
Transformation of Electrocompetent E. coli
One vial of electrocompetent E. coli was thawed on ice; 4 µL of the plasmid
ligation reaction were added and incubated on ice for 10 minutes. The mixture was
transferred to a chilled electroporation cuvette with a gap length of 0.1 cm and pulsed
once using the Micropulser machine (BioRad, Hercules CA) preset E. coli setting 1.
Immediately following electroporation, 250 µL of SOC media was added and the entire
mixture was transferred to a 1.5 mL microcentrifuge tube. The cells recovered at 37°C
for 1 hour, then plated on LB plates containing the appropriate antibiotic; plates were
incubated overnight at 37°C.

Construction of Expression Plasmid
The primer set AgSn35Fwd (BamHI site) and AgSn35Rev (XhoI site) were used
to PCR amplify the TvbA peptide AS01 from Sn35 gDNA with directional restriction sites
on either end of the PCR product. After gel electrophoresis and purification by gel
extraction, the PCR product was “A-tailed” by incubation with Taq DNA polymerase,
which adds an adenine to the 3’ end of DNA fragments. The 15 µL reaction was
composed of 10 µL PCR product, 1 µL 10 mM dNTPs, 2 µL sterile water, 1.5 µL Taq
buffer, and 0.5 µL Taq; this reaction was incubated at 72°C for 15 minutes. The A-tailed
PCR product was ligated into the pCR4-TOPO vector (Life Technologies, Carlsbad,
CA), which is a linear vector containing single, overhanging, 3’ deoxythymidine
residues. The 3 µL ligation reaction was composed of 2 µL of the previously A-tailed
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PCR product, 0.5 µL salt solution provided with the vector, and 0.5 µL of the pCR4TOPO vector. This reaction was incubated at room temperature for 20 minutes. All 3 µL
of the ligation reaction was used for transformation of CH3-Blue chemically competent
E. coli cells, as described previously. Transformants were selected for on LB agar
plates containing ampicillin. The plasmid construct was isolated and purified using the
previously mentioned plasmid miniprep kit, and sequence fidelity of the gene insert was
confirmed by nucleotide sequencing.
The pCR4-TOPO-AS01 plasmid construct was digested with BamHI and XhoI
(New England Biolabs, Ipswich, MA) according to the manufacturer’s instructions. The
isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible plasmid pET32xT (generously
supplied by Dr. David Williams, VCU, Richmond, VA) was also digested with BamHI
and XhoI. The digested PCR product was ligated into the digested plasmid using DNA
ligase, as described previously. The plasmid construct was used for transformation of
CH3-Blue chemically competent E. coli cells, as described previously. Transformants
were selected for on LB agar plates containing ampicillin. The plasmid construct was
isolated and purified using the previously mentioned plasmid miniprep kit. The
pET32xT-AS01 plasmid construct was used to transform electrocompetent E. coli BL21CodonPlus (DE3)-RIL cells (Stratagene, La Jolla, CA), as described previously.
Transformants were selected for on LB agar plates containing ampicillin and
chloramphenicol.
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Polyacrylamide Gel Electrophoresis
Gels were run using the NuPAGE SDS-PAGE system (Life Technologies,
Carlsbad, CA). Manufacturer’s instructions were followed with slight modifications.
Sample mixes consisted of 30 µL sample, 10 µL 4X Novex NuPAGE LDS Sample
Buffer (Life Technologies, Carlsbad, CA), and 4 µL 10X NuPAGE Sample Reducing
Buffer (Invitrogen, Grand Island, NY). Samples were placed in boiling water for 10
minutes, lightly sonicated, and loaded into the wells of a NuPage 4-12% Bis-Tris 1.5
mm gel (Invitrogen, Grand Island, NY). The gel was electrophoresed in 1X NuPAGE
Running Buffer for 35 minutes at 200 V. Protein size was determined by comparison
against the Precision Plus Protein Kaleidoscope standard (BioRad, Hercules, CA).
Lanes were visualized by staining the gel with Imperial Protein Stain (Thermo Scientific,
Waltham, MA) overnight, and destaining with water until bands were visible.

Recombinant Peptide Expression
To induce the expression of recombinant AS01, a streak of BL21+pET32xTAS01 colonies was used to inoculate 270 mL of LB containing ampicillin and
chloramphenicol. The culture was incubated with shaking overnight at 37°C. 120 mL of
the overnight culture was transferred to 2 L of LB containing ampicillin, and individual 60
mL aliquots of the overnight culture was transferred to 2 flasks of 1 L of LB containing
ampicillin. The cultures were then incubated shaking at 30°C for 3 hours. A 1 mL aliquot
of each culture was removed and saved prior to induction with 1 mM IPTG for 3 hours at
30°C. Following protein induction, another 1 mL aliquot was removed and saved. The
remaining culture volume was centrifuged to collect the bacterial cells. Pellets were
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washed one time in sterile 1X PBS, and frozen at -80°C. The pre- and post-induction
samples were run on a polyacrylamide gel, stained, and visualized in order to confirm
proper protein expression.

Recombinant Peptide Purification
Recombinant protein purification was conducted under denaturing conditions
following the Probond Purification System (Life Technologies, Carlsbad, CA) with
modifications. Each induced BL21+pET32xT-AS01 pellet was resuspended in 40 mL of
prewarmed guanidinium lysis buffer containing one dissolved EDTA-free protease
inhibitor tablet (Roche Diagnostics, Indianapolis, IN). Resuspended bacterial cells were
rocked at room temperature for 10 minutes, and then sonicated 6 times for 30 seconds
each. Cell debris was removed by centrifugation, and the supernatant was filter
sterilized using a syringe capped with a pre-filer and a 0.45 µm pore filter. 10 mL of
HisPur Cobalt Resin (Thermo Scientific, Waltham, MA) was washed once with sterile
water and once with denaturing binding buffer. The filtered protein supernatant was
applied to the beads in a 50 mL conical tube, and the tube was rocked at room
temperature for 20 minutes. A purification column was then prepared with the protein
supernatant + bead mixture. The column was washed once with denaturing binding
buffer, four times with denaturing wash buffer, and one time with denaturing elution
buffer containing no imidazole. Recombinant AS01 was eluted from the column with 5
mL denaturing elution buffer + 500 mM imidazole; 1 mL was added and collected at a
time. All fractions were pooled, concentrated, and loaded into a 3.5K MWCO Slide-ALyzer Dialysis Cassette (Thermo Scientific, Waltham, MA) to be dialyzed overnight in 3L
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of 10 mM Tris, pH 8.0 and 0.1% Triton X-100 stirring at 4°C. The dialyzed peptide was
removed from the dialysis cassette and total peptide concentration was determined
using a NanoDrop 1000 spectrophotometer (Thermo Scientific, Waltham, MA). In order
to determine the location of recombinant AS01 throughout the purification process,
fractions of all washes and elutions were run on a polyacrylamide gel, stained, and
visualized.

Western Analysis
A 0.45 µm PVDF transfer membrane (Thermo Scientific, Waltham, MA) was
soaked in an 80% methanol/20% ethanol solution, then dipped in 1X NuPage transfer
buffer (Invitrogen, Grand Island, NY) containing 10% methanol. Transfer paper and
sponges were also soaked in transfer buffer. After gel electrophoresis, the gel was
prepared for electrophoretic transfer by rinsing in deionized water and then placing
against the PVDF membrane. Transfer papers and sponges were used to maintain tight
contact between the gel and membrane. Transfers were run in 1X NuPage transfer
buffer at 45V for 90 minutes at room temperature. Membranes were blocked overnight
at 4°C in 5% skim milk diluted in 1X PBS, then probed with appropriate concentrations
of respective primary antibodies in 1X PBS + 1-1.5% blocking solution + 0.05% Tween20 (Fisher Scientific, Pittsburg, PA) for 1 hour at room temperature, while rocking.
Membranes were washed three times for 10 minutes with 1X PBST (PBS + 0.05%
Tween-20), then probed with 1:50,000-diluted goat anti-rabbit immunoglobulinhorseradish peroxidase conjugate (Invitrogen, Grand Island, NY) in 1X PBST for 45
minutes at room temperature, while rocking. Bands were visualized with the ECL Plus

	
  

	
   29	
  

	
  

western blotting detection system (GE Healthcare, Buckinghamshire, UK). Blots were
incubated in the chemiluminescence developing reagent for 30 seconds, covered in
plastic wrap, exposed to X-ray film, and developed in an X-O-Mat.

Rabbit Polyclonal Antiserum Production
Recombinant AS01 was expressed and purified using methods previously
described, and sent to New England Peptides. Prior to immunization with recombinant
AS01, 5 mL of pre-immunized serum was collected from the rabbit (New Zealand White
– SPF). The rabbit was immunized with recombinant AS01 3 separate times. Boosts
were administered on days 14 and 28, while bleeds were collected on days 35 and 40.
Upon receipt of post-immunized serum, serum was aliquoted into cryovials and stored
at -80°C.

Determining Location of TvbA Expression
A 5 mL overnight culture of Sn35 grown in SBHI+HS under anaerobic conditions
was centrifuged to obtain a cell pellet; the supernatant was concentrated, and the cell
pellet was resuspended and lysed in lysis buffer. Samples were subjected to SDSPAGE and Western analysis as described previously; the primary antiserum dilution
used in this experiment was 1:2500.

Temporal Protein Expression Assay
An overnight culture of Sn35 grown under anaerobic conditions in SBHI+HS was
subcultured at a 1:50 dilution into fresh SBHI+HS and grown at 37°C under anaerobic
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conditions. 1 mL samples were collected at 4, 6, 8, 12, 16, 24, and 48 hours. Cell pellets
were obtained by centrifugation at 16,000 rpm for 5 minutes at room temperature; after
storage at -80°C, pellets were resuspended in varying amounts of lysis buffer using
pellet size as a rough estimation of equal protein amounts. Samples were subjected to
SDS-PAGE and Western analysis as described previously; the primary antiserum
dilution used in this assay was 1:500.

Utilizing Antiserum in Inhibition Studies
Inhibition assays were performed as previously described, with modifications.
Bacteria were incubated with varying concentrations of pre-immunized serum or postimmunized serum for 30 minutes at 37°C in 5% CO2. Treated bacteria were then added
to cell monolayers and changes in cytopathogenicity were observed as previously
described.
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Results

I. Sn35 is Cytopathogenic to Host Cells

As previously discussed, it has been shown that Sn35 exerts cytotoxic effects on
Me-180 human cervical carcinoma cells, as observed by cell rounding and loss of
adherence58. Therefore, the first focus of this study was to identify additional
cytopathogenic effects caused by Sn35; for this focus, a variety of immortalized cell
lines were used. Immortalized cell lines were chosen due to their isolation from the
female reproductive system and their relevance to the study. Primary human amniotic
epithelial cells (HAECs) were also isolated and used in the study.

A. Cytotoxicity to HAECs
Sn35 was tested for its ability to induce loss of cell integrity (measured via a
trypan blue assay). 1.2 x 107 bacteria were added to a confluent monolayer of HAECs.
Following a 4 hour incubation, the monolayer was washed and incubated with trypan
blue for 4 minutes. The stain was removed and microscopic images were recorded. As
shown in Figure 3, epithelial cells treated with Sn35 are stained blue, indicating cell
damage and/or death due to incubation with Sn35. The trypan blue assay was repeated
using a 3 hour incubation time with similar results.
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Figure 3. Loss of cell integrity of HAECs due to incubation with Sn35. Bacteria
were grown in SBHI + HS anaerobically overnight. Bacteria were standardized to an
OD600nm = 0.1, and added to HAECs for 4 hours. Cells were washed after incubation,
and trypan blue was added for 4 minutes to determine reduction in cell integrity. Light
microscopy images were taken after the trypan blue incubation. Experiments were also
repeated using a 3 hour bacteria-host cell incubation.
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B. Cytotoxicity to JEG-3 cells
In addition to primary cells, we analyzed the ability of Sn35 to induce loss of cell
integrity and viability (measured via qualitative trypan blue assays and quantitative MTT
assays) in immortalized cell lines. 1.2 x 107 bacteria were added to a confluent
monolayer of JEG-3 human chorionic trophoblasts. Trypan blue and MTT assays were
performed as described previously. Figure 4 shows trypan blue cell integrity results for
JEG-3 cells. Treatment with Sn35 for 4 hours appears to inflict cell damage and/or
death, and allows for the trypan blue stain to traverse cell membranes. The trypan blue
assay was repeated using a 3 hour incubation time with similar results.
Figure 5 shows results representative of 2 biologic replicates of the MTT viability
assay for Sn35-induced cytotoxicity. After a 4 hour incubation of JEG-3 cells with Sn35,
the OD570nm readings, a measure of cell viability, had decreased to 25.9% relative to the
untreated controls. Those cells treated with 100% methanol for 4 hours had a
decreased viability of 9.7% relative to untreated controls. The MTT assay was repeated
with similar results.

C. Cytotoxicity to VK2 cells
The VK2 human vaginal keratinocyte cell line was also used to study cytotoxicity;
both trypan blue assays and MTT assays were performed as described above.
Consistent with trypan blue results from the JEG-3 cell line, exposure to Sn35 for 4
hours appeared to induce cell damage and/or death in the VK2 cell line (Figure 6). The
trypan blue assay was repeated using a 3 hour incubation time with similar results.
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Figure 4. Loss of cell integrity of JEG-3 cells due to incubation with Sn35. Bacteria
were grown in SBHI + HS anaerobically overnight. Bacteria were standardized to an
OD600nm = 0.1, and added to JEG-3 cells for 4 hours. Cells were washed after
incubation, and trypan blue was added for 4 minutes to determine reduction in cell
integrity. Light microscopy images were taken after the trypan blue incubation.
Experiments were also repeated using a 3 hour bacteria-host cell incubation.
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Figure 5. Loss of viability of JEG-3 cells due to incubation with Sn35. Bacteria
were grown in SBHI + HS anaerobically overnight. Bacteria were standardized to an
OD600nm = 0.1, and added to JEG-3 cells for 4 hours. Cells were washed after
incubation, and MTT was added to each well for 2 hours. After stop solution was added,
A570nm readings were collected via a 96-well plate reader to determine cell viability.
Statistical comparison (using student t-test) between Sn35-treated cells and the control
cells gave a P value of <0.05. Experiments were performed twice with similar results;
this is a representative graph of viability.
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Figure 6. Loss of cell integrity of VK2 cells due to incubation with Sn35. Bacteria
were grown in SBHI + HS anaerobically overnight. Bacteria were standardized to an
OD600nm = 0.1, and added to VK2 cells for 4 hours. Cells were washed after incubation,
and trypan blue was added for 4 minutes to determine reduction in cell integrity. Light
microscopy images were taken after the trypan blue incubation. Experiments were also
repeated using a 3 hour bacteria-host cell incubation.
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Figure 7 shows results representative of 2 biologic replicates of the MTT viability
assay for Sn35-induced cytotoxicity. After a 4 hour incubation of VK2 cells with Sn35,
the OD570nm readings had decreased to 63.5% relative to the untreated controls. Those
cells treated with 100% methanol for 4 hours had a decreased viability of 7.3% relative
to untreated controls. The MTT assay was repeated with similar results.	
  

II. Adherence and Invasion of Host Cells

Previous studies have also demonstrated adherence of Sn35 to the Me-180 cell
line58. Sn35 was therefore tested for its ability to adhere to the cell lines previously
described. In addition, Sn35 invasion of host cells was also studied, as some bacterial
species invade host cells after adhering to their surfaces.

A. Adherence and Invasion of HAECs
Confocal microscopy was used to determine if Sn35 was capable of adhering
and/or invading HAECs. Epithelial cells were stained with VyBrant DiI membrane stain,
while bacterial cells were stained with BacLight Green bacterial stain. Cells and bacteria
were incubated together for 15 minutes, and then cell monolayers were washed and
imaged with a Zeiss LSM 710 Confocal Microscope. Figure 8 indicates that Sn35 is
able to invade HAECs, as demonstrated by the fluorescence of the bacteria within the
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Figure 7. Loss of viability of VK2 cells due to incubation with Sn35. Bacteria were
grown in SBHI + HS anaerobically overnight. Bacteria were standardized to an OD600nm
= 0.1, and added to VK2 cells for 4 hours. Cells were washed after incubation, and MTT
was added to each well for 2 hours. After stop solution was added, A570nm readings were
collected via a 96-well plate reader to determine cell viability. Statistical comparison
(using student t-test) between Sn35-treated cells and the control cells gave a P value of
<0.05. Experiments were performed twice with similar results; this is a representative
graph of viability.
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Figure 8. Invasion of Sn35 into HAECs. Bacteria were grown in SBHI + HS
anaerobically overnight. Bacteria (green) were standardized to an OD600nm = 0.150, and
added to HAECs (red) for 15 minutes. Cells were washed after bacterial incubation to
remove any nonadherent bacteria. Adherence was observed by confocal microscopy.
Experiments were performed twice, with similar results.
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epithelial cell. A Z-stack was also performed to confirm the presence of Sn35 within the
cell (Figure 9). The confocal assay was performed two times with similar results.

B. Adherence and Invasion of JEG-3 cells
Confocal assays were performed on the JEG-3 cell line as described above.
Figure 10 shows that Sn35 appears to some interaction with this cell line; however, the
interaction is not as pronounced as that of Sn35 and HAECs. This assay was performed
two times with similar results.
In addition to confocal assays, several other adherence and invasion assays
were performed with the JEG-3 cell line. qPCR was used to determine the amount of
bacteria that adhered and invaded JEG-3 cells during a 1 hour incubation. Figure 11
demonstrates that 4.2% of Sn35 added to each well was recovered by qPCR relative to
the amount of bacterial input. The qPCR assay was performed two times with
inconsistent results. Plating assays were also performed to obtain adherence and
invasion percentages. Figure 12 demonstrates that, through plating recovery
experiments, 1.7% of bacteria were able to adhere to JEG-3 cells relative to the
bacterial input, while 0.3% of bacteria were able to invade the JEG-3 cells. Plating
assays were performed two times with inconsistent results.

C. Adherence and Invasion of VK2 cells
Confocal, adherence, and invasion assays were performed on the VK2 cell line
as described above. Figure 13 demonstrates that Sn35 is able to invade VK2 cells, as
shown by confocal microscopy. This assay was performed twice with similar results.
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Figure 9. Z-stack of Sn35 invasion into HAECs. Successive slices of different focal
planes were used to confirm invasion of bacteria into the cells.
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Figure 10. Invasion of Sn35 into JEG-3 cells. Bacteria were grown in SBHI + HS
anaerobically overnight. Bacteria (green) were standardized to an OD600nm = 0.150, and
added to JEG-3 cells (red) for 15 minutes. Cells were washed after bacterial incubation
to remove any nonadherent bacteria. Adherence was observed by confocal microscopy.
Experiments were performed twice, with similar results.
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Figure 11. qPCR-based recovery of Sn35 after incubation with JEG-3 cells.
Bacteria were grown anaerobically in SBHI + HS overnight. The culture was
standardized to OD600nm = 0.1, and incubated with JEG-3 cells for 1 hour. DNA was
extracted and subjected to qPCR with Sn35-specific 16S primers.
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Figure 12. Adherence and invasion of JEG-3 cells by Sn35. An overnight Sn35
culture was standardized to OD600nm = 0.1 for adherence studies and 0.001 for
gentamicin protection studies. Cells were incubated for an hour with bacteria;
gentamicin assays were incubated with the antibiotic for an additional hour. Percent
adherence and invasion were calculated from CFUs plated on SBHI + chocolate agar.
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Figure 13. Invasion of Sn35 into VK2 cells. Bacteria were grown in SBHI + HS
anaerobically overnight. Bacteria (green) were standardized to an OD600nm = 0.150, and
added to VK2 cells (red) for 15 minutes. Cells were washed after bacterial incubation to
remove any nonadherent bacteria. Adherence was observed by confocal microscopy.
Experiments were performed twice, with similar results.

	
  

	
   56	
  

	
  

	
  

	
   57	
  

	
  

Figure 14 demonstrates that 7.3% of Sn35 added to each well was recovered by qPCR
relative to the amount of bacterial input. As with the JEG-3 cell line, the qPCR assay
was performed two times with inconsistent results. Figure 15 demonstrates that,
through plating recovery experiments, 1.4% of bacteria were able to adhere to VK2 cells
relative to the bacterial input, while 0% of bacteria were able to invade the VK2 cells.
Plating assays were performed two times with inconclusive results.

III. Identification of Putative Virulence Gene in Sn35

Bioinformatic analysis of the Sn35 genome revealed a putative virulence gene
with homology to a number of haemagluttinin repeats and haemagglutination activity
domains; homology to a filamentous haemagglutinin family domain was also identified.
One well-studied filamentous haemagglutinin, FHA, is expressed by Bordetella
pertussis. FHA is the best-studied adhesin produced by B. pertussis, and requires a
single specific accessory protein, FhaC, for secretion. FHA and FhaC work together as
components of a two-partner Type Vb two-partner secretion system (Figure 16). FHA
begins as a precursor with an N-terminal signal peptide that is recognized by the Sec
pathway machinery. Once through this machinery, FhaC both aids in the folding of FHA
and mediates the secretion of the mature FHA protein by forming a pore in the outer
membrane. Because a potential virulence factor was identified, additional analyses
were performed to find a putative transporter gene in the Sn35 genome. Upstream of
the previously identified putative virulence gene, a gene with homology to
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Figure 14. qPCR-based recovery of Sn35 after incubation with VK2 cells. Bacteria
were grown anaerobically in SBHI + HS overnight. The culture was standardized to
OD600nm = 0.1, and incubated with VK2 cells for 1 hour. DNA was extracted and
subjected to qPCR with Sn35-specific 16S primers.
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Figure 15. Adherence and invasion of VK2 cells by Sn35. An overnight Sn35 culture
was standardized to OD600nm = 0.1 for adherence studies and 0.001 for gentamicin
protection studies. Cells were incubated for an hour with bacteria; gentamicin assays
were incubated with the antibiotic for an additional hour. Percent adherence and
invasion were calculated from CFUs plated on SBHI + chocolate agar.
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Figure 16. Type Vb two-partner secretion system expressed by Bordetella
pertussis, and putatively expressed by Sn35. The secreted protein is represented in
green, and red represents the signal peptide cleaved off of the protein after
translocation through the Sec pathway (shown in maroon). The transporter protein is
represented in orange, which helps to fold the protein into its functional conformation
and aids in its secretion through the outer membrane. Figure adapted from Thanassi et
al., 200062.
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FhaC was identified. This was not surprising, as genes encoding Type Vb two-partner
systems are organized into operons, where the transporter gene usually precedes the
virulence gene63. Because many virulence factors are secreted by two-partner secretion
systems, the putative genes in Sn35 became the targets of this study. The putative
virulence protein was designated TvbA, for putative Type Vb protein A; the putative
transporter protein was designated TvbB, for putative Type Vb protein B. TvbA is
approximately 1715 amino acids and 184.55 kDa in size, and TvbB is approximately
441 amino acids and 50.63 kDa in size.

IV. Polyclonal Antiserum Production Using TvbA Peptide

In order to study the newly identified TvbA, attempts to clone and express the
full-length, functional protein were made. However, these were unsuccessful; one
difficulty encountered was the complexity of the putative two-partner system. If TvbA
does utilize a two-partner secretion system, the putative transporter TvbB would be
absolutely necessary for the proper folding and secretion of the putative virulence
protein. Therefore, both proteins would need to be cloned and expressed together in
order to produce functional TvbA. The two-gene operon is 6.483 kb in size. Purified
TvbA would also be difficult to obtain; inserting a purification tag between the two
secretory components might disturb secretion, as the N-terminus of the protein encodes
a signal sequence prior to processing. Additionally, previous studies have demonstrated
that virulence components of two-partner systems can contain C-terminal domains that
are removed during translocation64. If further processing occurs at the C-terminus of
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TvbA, a C-terminal purification tag would be cleaved off and rendered useless. For
these reasons, an alternate tactic was developed. Upstream and downstream fragments
of TvbA were amplified via PCR, fused to a chloramphenicol resistance cassette, and
cloned into a suicide vector for use in generating a TvbA gene interruption via allelic
exchange. Currently, this approach has also been unsuccessful. As previously
discussed, a genetic system has not been established for Sn35, making modification
difficult. Due to the inability to work with recombinant full-length TvbA or purify the
protein, polyclonal antiserum to a fragment of TvbA was produced.

A. Identification of Antigenic Epitopes within TvbA
In order to identify the regions of TvbA with the highest antigenic propensity, the
amino acid sequence of the full-length protein was submitted to an online antigenic
peptide predictor, which compares the occurrence of amino acid residues in submitted
protein sequence to those found in experimentally determined epitopes. According to
the prediction algorithm used, if the average antigenic propensity for the whole protein is
above 1.0, all residues with a propensity of above 1.0 are potentially antigenic. If the
average is below 1.0, all residues with a propensity above the average of the total
protein are potentially antigenic61. The average antigenic propensity for TvbA is 0.9937,
according to this algorithm. The results obtained from the predictor are shown in Figure
17.
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Figure 17. In silico prediction of antigenic epitopes within TvbA. Average antigenic
propensities generated for TvbA demonstrated a number of antigenic epitopes in the
middle of the protein. The peptide targeted for antiserum production is boxed.
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While epitope prediction tools are helpful, they only provide estimations.
When choosing a peptide for antiserum production, the N- or C-terminal of the fulllength protein is typically used, as those parts of the protein are usually exposed65.
However, as previously mentioned, using the termini of TvbA as antiserum targets
would be risky. Therefore, the middle of TvbA was targeted for eventual polyclonal
antiserum production. It was thought that by selecting a larger peptide, the polyclonal
antiserum would be able to detect multiple epitopes present in TvbA. This is ideal for
our current studies, as the conformation of functional TvbA is currently not known. The
target peptide was 60.50 kDa in size without purification tags; the vector tags added ~20
kDa to the final peptide size. This peptide fragment is referred to as AS01. The boxed
area in Figure 17 indicates the targeted peptide region.

B. Expression and Purification of Recombinant AS01
AS01 was amplified by PCR as previously described (Figure 18). AS01 was
cloned into the pCR4-TOPO vector, digested out using restriction enzymes, and
subsequently subcloned into digested pET32xT (Figure 19). Presence of the fragment
was confirmed via sequencing and restriction digest (Figure 20). After transformation
into E. coli cells and verification of transformants, recombinant AS01 was expressed
with samples collected both pre- and post-induction. Whole cell lysates obtained preinduction and post-induction were subjected to SDS-PAGE and visualized as previously
described. Expression of the TvbA fragment was confirmed by the presence of an ~80
kDa product after induction with 1 mM IPTG (Figure 21). Expressed recombinant AS01

	
  

	
   69	
  

	
  

Figure 18. PCR amplification of AS01 DNA. AS01-specific primers were used to
amplify AS01 off of the Sn35 genome. Lane 1 contains Hyperladder 1kb, and Lane 4
contains AS01 (1680 bp in size). PCR products were run on 1% agarose DNA gel.
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Figure 19. Schematic representation of the pET32xT-AS01 plasmid. The AS01
peptide is shown in green. The peptide is tagged with 2 6xHis tags: one at the 5’ end of
the insert and one at the 3’ end.
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Figure 20. Restriction digest confirmation of pET32xT-AS01 candidates in
chemically competent E. coli cells. Lane 1 contains Hyperladder 1kb, Lane 2 is
empty, and Lanes 3-11 are candidates digested with XbaI. All candidates (except the
one in Lane 8) exhibit the expected banding pattern (6547 bp and 1005 bp). Candidate
1 (Lane 3) was used in this study.
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Figure 21. Confirmation of induced AS01 with 1mM IPTG at 30°C. An SDS-PAGE
gel was Imperial-stained and used to confirm the presence of AS01 after IPTG induction
(Lane 3, boxed band). Lane 1 contains protein ladder. Lane 2 contains a pre-induced
culture sample.
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was purified via column purification utilizing cobalt resin (Figure 22). After dialysis, the
purified peptide was sent to New England Peptides for polyclonal antiserum generation.

C. Characterizing the Expression of TvbA in Sn35 Using AS01 Antiserum
AS01 antiserum was first used to identify the localization of TvbA expression in
Sn35. To determine whether TvbA is associated with the bacterial cell surface or
secreted into bacterial media, an overnight culture of Sn35 was centrifuged and
separated. Fractions of cell pellets and cell supernatants were subjected to SDS-PAGE
and Western analysis as previously described. TvbA was detected in the cell pellet
fraction, as depicted by Figure 23, suggesting that the protein is not secreted into
bacterial media. According to the genome sequence of Sn35, TvbA should be 184.55
kDa in size. However, the bands detected appear to be much bigger than that. It’s
possible that TvbA is modified in some way; it’s also possible that the protein is
dimerizing.
To further characterize the expression of TvbA in a temporal context, samples of
an actively growing Sn35 culture were collected and subjected to SDS-PAGE and
Western analysis. TvbA appears to be expressed throughout exponential, late
exponential, and stationary phases (Figure 24). Again, the protein is detected at a size
above 250 kDa. However, a smaller band that appears to sit at ~180 kDa appears over
time. This could further support the hypothesis that TvbA is dimerizing.
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Figure 22. Purification of recombinant AS01. Fractions obtained from cobalt resin
column purification were run on an SDS-PAGE gel and Imperial-stained. Lane 1
contains protein ladder. Lane 2 contains a sample of culture lysate. Lane 3 contains
flow through after initial application of culture lysate to the resin, and Lane 4 contains a
single wash with denaturing binding buffer. Lanes 5 and 6 contain the first and last
washes with denaturing wash buffer. Lane 7 contains one wash with denaturing elution
buffer containing no imidazole. Lanes 8 and 9 contain the eluted AS01 peptide with
denaturing elution buffer and 500mM imidazole (boxed), and Lane 10 indicates cobalt
resin remaining in the column.
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Figure 23. Characterization of the subcellular location of TvbA in Sn35. Western
analysis using TvbA antiserum demonstrated that TvbA is localized in the cell pellet
(Lane 3) and outer membrane proteins (Lane 4), as indicated by the boxed bands. Lane
2 shows concentrated supernatant; TvbA was not present in that fraction. Lane 1
contains protein ladder.
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Figure 24. Temporal expression of TvbA by Sn35. TvbA is expressed through
exponential, late exponential, and stationary phase. TvbA appears to be detected above
250 kDa, as indicated by the boxed bands. Lane 1 contains protein ladder.
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D. Inhibiting Cytotoxicity, Adherence, and/or Invasion Using AS01 Antiserum
Following successful detection of TvbA using antiserum, inhibition studies of
cytotoxicity, adherence, and invasion were performed. Trypan blue assays were
performed on the JEG-3 cell line to determine the inhibition effects of antiserum. Sn35
incubated with a 1:100 dilution of antiserum was still able to induce cell damage and/or
death to the host cells (Figure 25). Incubation with pre-immunized serum also had no
effect on cytotoxicity (data not shown). Assays were repeated with antiserum dilutions of
1:1000 and similar results were observed.
Furthermore, confocal assays were performed on the VK2 cell line to determine if
antiserum blocked the adherence and/or invasion of host cells. Sn35 incubated with a
1:100 dilution of antiserum was still able to invade the VK2 cells, as shown in Figure 26.
Again, incubation with pre-immunized serum had no effect on invasion (data not
shown). Assays were repeated with antiserum dilutions of 1:1000, and similar results
were observed.
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Figure 25. Inhibition of Sn35 cytotoxicity to JEG-3 cells. Bacteria were grown in
SBHI + HS anaerobically overnight. Bacteria were standardized to an OD600nm = 0.1,
and incubated with a 1:100 dilution of antiserum for 30 minutes at 37C. Bacteria were
added to JEG-3 cells for 4 hours. Cells were washed after incubation, and trypan blue
was added for 4 minutes to determine cell viability. Light microscopy images were taken
after the trypan blue incubation. This experiment was repeated with a 1:1000 dilution of
antiserum, with similar results.
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Figure 26. Inhibition of Sn35 adherence to VK2 cells. Bacteria were grown in SBHI +
HS anaerobically overnight. Bacteria (green) were standardized to an OD600nm = 0.150,
and incubated with a 1:100 dilution of antiserum for 30 minutes at 37C. Bacteria were
added to VK2 cells (red) for 15 minutes. Cells were washed after bacterial incubation to
remove any nonadherent bacteria. Adherence was observed by confocal microscopy.
This experiment was repeated with a 1:1000 dilution of antiserum, with similar results.
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Discussion

Although Sneathia has been implicated in a number of obstetric complications
and is one of the most common bacterial species isolated from amniotic fluid, the
specific role of S. amnii strain Sn35 in preterm births caused by MIAC is still unclear.
Through this study, the pathogenic potential of Sn35 was further characterized by
assessing its effects on host cells, as well as its production of a putative virulence
determinant.
The first research focus of this study was on the pathogenicity of Sn35 and its
effect on various cell lines. It was hypothesized that Sn35 damaged and/or traversed
host cell barriers formed during pregnancy, allowing it to invade the amniotic cavity. This
hypothesis was confirmed, as our data demonstrates the ability of Sn35 to adhere,
invade, and kill host cells.
In the current study, MIAC is modeled using immortalized and primary cell lines.
While these models are able to provide some insight on bacterial-host cell interactions,
they leave much to be desired. At this time, the specific cell target of Sn35 is unknown.
Because fetal membranes are multi-layered and contain a variety of cell types, it’s
possible that the host cells upon which Sn35 acts were not tested in this study. Primary
HAECs were thought to be the best model for this focus; however, isolation and
maintenance of these cells was difficult.
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Another obstacle to overcome is the translation of studies in vitro to infection in
vivo. The placenta is designed to withstand a growing fetus for 9 months; even in cases
of very preterm birth, such as the circumstance under which Sn35 was isolated,
membranes have been in place for several weeks. Currently, it is not known how long it
takes for Sn35 to access the amniotic cavity in vivo. We assume that this process is
gradual, and most likely doesn’t occur in the short time periods that we have tested in
vitro. Relevant studies have utilized mice, rabbit, and sheep models to study preterm
birth and therapeutic targets aimed at improving neonatal outcome66. The ideal animal
model for human pregnancy is the nonhuman primate, as their placentation and
hormonal events occurring during pregnancy most closely resemble those of humans66.
While animal models were not used for this study, further characterization of Sn35 in the
context of preterm birth would benefit from their use.
The second objective concentrated on the identification of putative virulence
determinants that could cause the observed pathogenic effects seen with Sn35-treated
host cells. It was hypothesized that some virulence factor must be produced in order for
cytopathogenicity to occur. Bioinformatic analyses identified a protein within Sn35 that
had homology to haemagluttinin domains/repeats and adhesins. A putative Type Vb
two-partner secretion system was identified as being the possible mechanism by which
the putative virulence factor is secreted; a putative transporter gene was identified
directly upstream of the putative virulence gene, indicating that the two genes are
components of a two-partner secretion system.
The third objective focused on characterizing the function of the putative
virulence factor. It was hypothesized that the putative virulence factor was acting as a
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cytotoxin or adhesin. At this time, this hypothesis has yet to be confirmed, as antiserumtreated bacteria were still able to invade host cells and induce cell damage and/or
death. This could be due to a number of reasons; one plausible explanation is that TvbA
is acting as neither a cytotoxin nor an adhesin. According to bioinformatic analyses, this
is not likely, as the majority of known protein sequences that produce significant
alignment with TvbA are adhesins or toxins.
A second explanation is that the polyclonal antiserum is not specific for many of
the epitopes of native TvbA. The AS01 fragment used for polyclonal antiserum
production may have a different conformation compared to native TvbA; this would
result in the generation of antibodies specific to epitopes found on the fragment, but not
the native protein. One additional explanation is that the antibodies specific for native
TvbA epitopes could be blocked from binding due to steric hindrance. It’s possible that
the antibodies within the antiserum are too bulky to bind to their specific epitopes.
Additional experiments with the polyclonal antiserum, to include antibody fragmentation,
will need to be performed to confirm or disprove this hypothesis.
Surprisingly, native TvbA was detected at ~250 kDa or above in all Western
analyses. Currently, the genome sequence of Sn35 places the protein size at ~180 kDa.
It’s possible that several repeats exist within the TvbA sequence, and misassemblies
during genome sequencing caused the collapsing of these repeats. Post-translational
modification, such as glycosylation or phosphorylation, would also explain the increase
in protein size. An increase of ~60 kDa or higher, as observed in our analyses, could
indicate modifications at multiple amino acids. Finally, TvbA could be forming a dimer.
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This would explain the presence of smaller bands (~180 kDa) seen during temporal
expression studies.
Collectively, the results of this study signify the need for further research into S.
amnii strain Sn35 and the role it plays in preterm birth. Although Sn35 is not solely
responsible for eliciting MIAC and PPROM, there is no doubt that it possesses the
pathogenicity potential to contribute to these obstetric complications. The presence of
Sn35 in vaginal and AF samples acquired from preterm births makes the organism one
worth studying. While the findings presented in this work have further built upon the
current understanding of Sn35, they have only scratched the surface. Therefore, having
a better understanding of this organism will, in turn, result in a more complete
knowledge of how MIAC, PPROM, and, ultimately, preterm birth develop.
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